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Abstract: Herein, we report an environmentally friendly, rapid, and convenient ionic liquid
([Et3NH][HSO4])-promoted facile synthesis of ethyl 4-(6-substituted-4-oxo-4H-chromen-3-yl)-6-methyl-
2-thioxo/oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate derivatives 4(a–f) and 4-(6-substituted-4-
oxo-4H-chromen-3-yl)-6-methyl-2-thioxo/oxo-1,2,3,4-tetrahydropyrimidine-5- carbohydrazide derivatives
6(a–f). All the synthesized derivatives 4(a–f) and 6(a–f) were evaluated for their in vitro antifungal
and antibacterial activity, by method recommended by National Committee for Clinical Laboratory
Standards (NCCLS). The compound 6c bearing a fluoro group on the chromone ring and oxygen and
a hydrazino group (–NHNH2) on the pyrimidine ring, was found to be the most potent antibacterial
compound amongst the synthesized derivatives. The compound 6f bearing a methoxy group (–OCH3)
on the chromone ring and sulphur group on the pyrimidine ring, was found to exhibit equipotent
antifungal activity when compared with the standard drug miconazole. A D-alanine-D-alanine
ligase (DdlB) enzyme assay study and an ergosterol extraction and quantitation assay study were
performed to predict the mode of action of the synthesized compounds. A molecular docking
study was performed to predict the binding interactions with receptors and mode of action of the
synthesized derivatives. Further, analysis of the ADMET parameters for the synthesized compounds
has shown that these compounds have good oral drug-like properties and can be developed as oral
drug candidates. To establish the antimicrobial selectivity and safety, the most active compounds 6c
and 6f were further tested for cytotoxicity against the human cancer cell line HeLa and were found
to be non-cytotoxic in nature. An in vivo acute oral toxicity study was also performed for the most
active compounds 6c and 6f and the results indicated that the compounds are non-toxic in nature.
Keywords: ionic liquid; antifungal activity; antibacterial activity; molecular docking; cytotoxicity;
in vivo acute oral toxicity
1. Introduction
In the past few decades many drug-resistant human pathogenic microbes have been observed [1]
and this is a serious public health dilemma in a wide range of infectious disease [2,3]. Failure in the
antimicrobial treatment is mostly observed due to the resistance developed in the microbes, which
leads to increased risks to mortality and sometimes contributes to complications. To prevail over this
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challenge the best way is the design and development of novel bioactive compounds which will be
effective against strains which have developed resistance. In spite of the large number of antibiotics
and chemotherapeutics available for medical use, antimicrobial resistance has created a substantial
medical need for new classes of antimicrobial agents. The design and synthesis of novel antimicrobials
agents will forever remain an area of gigantic connotation [4,5]. Novel and potent antimicrobial agents
can be obtained by revamping the structure of the available antimicrobial agents or combining together
two or more different active pharmacophores present in antimicrobial agents into one molecule.
Coumarins are an elite class of naturally occurring compounds with promising therapeutic
perspectives [6,7]. This compound has become obligatory structural unit that is utilitarian in
medicinal chemistry, with a wide variety of activities such as anticancer [8], antioxidant [9],
antiplasmodial [10], antimalarial [11], antirhinovirus [12], antifungal [13] and antibacterial
properties [14]. 4-oxo-4H-Chromen-3-carbaldehyde (3-formylchromone) is a most significant starting
point for the synthesis of quite a lot of biologically active compounds due to the existence of an
unsaturated keto functional group, a conjugated second carbonyl group at the C-3 position, and
an electrophilic centre at the C-2 position. Much research has been focused on the inhibition of
bacterial growth using naturally occurring coumarins such as xanthoxin, herniarin, umbelliferone,
and scopoletin and on the antifungal activity of umbelliferone, scopoletin, and coumarin itself [15].
The coumarin scaffold is present in many antimicrobial agents such as semigrabrin, novobiocin,
quercetin, apigenin, etc.
Nitrogen-containing heterocycles such as pyrimidine are a subject of continuous interest because
of their diverse biological activities and occurrence in natural medicinal plants. Pyrimidine and its
derivatives are used as pesticides, herbicides and insecticides [16,17]. Marketed antifungal drugs such
as flucytosine, voriconazole and albaconazole also contain pyrimidine nuclei [18].
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Molecular hybridization is a rational drug design approach whereby new chemical entities are
obtained by combining two or more pharmacophoric units from different bioactive compounds into
a single molecule. Through this approach, medicinal chemists hope that the new hybrid derivatives
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will present better affinity and efficacy when compared to the individual parent drugs, a modified
selectivity profile with improved pharmacokinetic and pharmacodynamic properties, dual or multiple
modes of action, reduction of undesirable side effects, decreases in drug-drug interactions, reduced
emergence or spread of drug resistance in microorganisms and protozoans and lower cost [19].
Pharmacophore hybridization is believed to be analogous to conventional combination therapy, with
the exception that the two pharmacophores are covalently linked and available as a single entity.
The selection of the two principles in the dual molecule is usually based on their observed (or
anticipated) synergistic or additive pharmacological activities to enable the identification of highly
active novel chemical entities [20–23]. In view of this and in continuation to our search for more
effective antifungal and antibacterial agents [24–28], we planned the synthesis of coupled systems
containing coumarin and pyrimidine rings with appropriate pharmacophores. The design protocol
for the synthesized derivatives is as shown in Scheme 1. Considering the importance of both these
scaffolds the molecular hybridization technique was used to couple them together, in the hope to
getting newer derivatives with the higher antimicrobial activity.
Considering the focus on green synthesis in recent years, ionic liquids have attracted the attention
of many researchers. Ionic liquids have been referred to as “designer solvents/green solvents”
because of their physical and chemical properties which can be adjusted by varying the cation
and anion. Taking into consideration the abovementioned points, we have carried out the synthesis of
coumarin-pyrimidine coupled hybrid derivatives 4(a–f) and 6(a–f) using triethylammonium hydrogen
sulphate [Et3NH][HSO4] as an solvent and easily recoverable green catalyst [26].
All the synthesized ethyl 4-(6-substituted-4-oxo-4H-chromen-3-yl)-6-methyl-2-thioxo/oxo-1,2,3,4-
tetrahydropyrimidine-5-carboxylate derivatives 4(a–f) and 4-(6-substituted-4-oxo-4H-chromen-3-yl)-6-
methyl-2-thioxo/oxo-1,2,3,4-tetrahydropyrimidine-5-carbohydrazide derivatives 6(a–f) were screened
for their in vitro antifungal and antibacterial activity, by the method recommended by National
Committee for Clinical Laboratory Standards (NCCLS), using miconazole and D-cycloserine as
standard drugs, respectively. Minimum inhibitory concentration (MIC100) values were determined
using the standard agar method as per CLSI guidelines [26,29–31].
The drug target selection was based on different biological roles such as: (i) cell wall synthesis;
(ii) protein synthesis; (iii) nucleic acid synthesis; and (iv) cell metabolism [26]. ATP-dependent
D-alanine-D-alanine ligase (Ddl) is one of the parts of biochemical machinery which is involved in
biosynthesis of peptidoglycan, as it catalyzes the formation of the terminal D-ala-D-ala dipeptide
of the peptidoglycan precursor UDP MurNAc pentapeptide. Bacterial growth is inhibited if the
enzyme D-alanine ligase (Ddl) is been inhibited by the designed molecule. D-Alanine ligase (Ddl)
enzyme inhibition is an attractive and tenable target in the search for novel and effective antimicrobial
drugs [32]. Recently, coumarin derivatives have been reported to inhibit E. coli DdlB enzyme [33].
Hence, the designed and synthesized compounds were appraised for their inhibiton effect using
D-alanine-D-alanine ligase (DdlB) enzyme assay study.
The main function of most antifungal agents is to prevent the synthesis of ergosterol, which is a
key element of the fungal plasma membrane. Lanosterol 14α-demethylase enzyme plays an important
role in ergosterol synthesis in fungi [18]. Exposure of fungi to lanosterol 14α-demethylase enzyme
inhibitors causes reduction of ergosterol. This restricts and disturbs the structure of the membrane
and its nutrient transport and chitin synthesis functions. The net result is to inhibit fungal growth.
Most fungi cannot survive without ergosterol, and the enzymes that participate in its formation have
become important targets for drug discovery. Recently, coumarin derivatives have been reported to
inhibit cytochrome P450 lanosterol 14α-demethylase (CYP51) [34]. Based on literature reports [35]
and the antifungal activity exhibited by the synthesized compounds, an ergosterol extraction and
quantitation assay method was used to study the mode of action of the most potent antifungal
compound 6f [26].
Molecular docking is a well-known computational method for drug discovery which can be
used to mock-up the interaction between a ligand and a protein at the atomic level and to predict,
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and characterize the behavior of ligands in the binding site of target proteins [36]. The synthesized
compounds were thus docked into a homology model of cytochrome P450 lanosterol 14α-demethylase
of C. albicans [37] to predict their antifungal activity mode of action. The synthesized compounds were
also docked into the E. coli DdlB enzyme (PDB entry: 1IOV [38]) to predict its antibacterial activity
mode of action [26].
To evaluate the drug-like properties of the synthesized compounds, the physicochemical
parameters based on the Lipinski RO5 (Rule of Five) [39] and Jogersons rule of three were determined
using Qikprop v. 3.5 (Schrodinger LLC). This pharmacological investigation of the compounds can
support pharmaceutical scientist in selecting the most effective compounds for the development of
better drugs [26]. Cytotoxicity studies and in vivo acute oral toxicity examinations of the most active
synthesized compounds 6c and 6f were also performed.
2. Result and Discussion
2.1. Chemistry
The utility of triethylammonium hydrogen sulphate [Et3NH][HSO4] in molten state, which is a
low cost, mild, non-volatile and non-corrosive acidic ionic liquid, as an efficient Bronsted acid catalyst
under solvent-free conditions for the Biginelli reaction is described, as shown in Scheme 2.
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Scheme 2. Scheme for green synthesis of the target co pounds 4(a–f) and 6(a–f).
The model reaction of 4-oxo-4H-chromene-3-carbaldehydes, ethyl acetoacetate and urea in
[Et3NH][HSO4] was optimized by investigating various parameters such as the mol percent of catalyst
at various temperatures. The triethylammonium hydrogen sulphate [Et3NH][HSO4] ionic liquid was
screened as catalyst at various loads such as 5, 10, 15, 20 mol % and at various temperatures such as 80,
90, 100, 110 ◦C as shown in Table 1. When 5 mol % of the catalyst was used at 100 ◦C the product 4a
was obtained in 72% yield in 150 min. Furthermore, the effect of the amount of catalyst was examined
by examining the effect of various catalyst loads on the yield of product and the time required for
completion of reaction for co pound 4a. When 10 mol % of catalyst was used at 100 ◦C, compound 4a
was obtained in 76% yield in 105 min. When 15 mol % of catalyst was used at 100 ◦C, 95% of 4a was
obtained in 60 min. The same yield resulted when 20 mol % of catalyst was used at 100 ◦C. Therefore,
considering 15 mol % as an efficient amount the reactio was carried t at va ious temperatures
like 80 ◦C, 90 ◦C, 100 ◦C and 110 ◦C. Temperatures both above and below 100 ◦C gave lower yi lds,
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therefore 15 mol % of the [Et3NH][HSO4] ionic liquid as catalyst and solvent at 100 ◦C was considered
to give the best yield (95%) in the shortest reaction time (60 min) (Entry 3 of Table 1).
Table 1. Effect of different reaction conditions on [Et3NH][HSO4] catalyzed synthesis of 4a.
Entry Temperature (◦C) Catalyst (mol %) Time (min) Yield (%)
1 100 5 150 77
2 100 10 105 76
3 100 15 60 95
4 100 20 60 95
5 110 15 65 91
6 90 15 80 70
7 80 15 85 70
These observations make the process under study more expeditious, economic, safe and eco-friendly.
The recovery and reusability of the catalyst was investigated for the synthesis of compound 4a.
The results are given in Table 2; the recovered catalyst can be reused for at least four additional times
in subsequent reactions without a considerable decrease in its catalytic activity.
Table 2. Reusability of [Et3NH][HSO4] catalyst for model reaction 4a.
Entry Run Time Yield
1 1 60 95
2 2 60 90
3 3 60 88
4 4 60 77
A total of six novel ethyl 4-(6-substituted-4-oxo-4H-chromen-3-yl)-6-methyl-2-thioxo/oxo-1,2,3,4-
tetrahydropyrimidine-5-carboxylate derivatives 4(a–f) were synthesized according to the
abovementioned green synthetic protocol. The time required for the completion of reactions was
around 60–85 min time (monitored by TLC). The yields of the synthesized novel compounds were
in the 86–95% range. The structures of the synthesized compounds were confirmed by IR, 1H-NMR,
13C-NMR, mass spectral analysis and elemental analysis.
The synthesized derivatives 4(a–f) (1 mmol) were next allowed to react with hydrazine hydrate
(1.2 mmol) under solvent free condition using [Et3NH][HSO4] as a catalyst and also as a solvent to
furnish compounds 6(a–f). The catalyst load and the temperature required for the synthesis of 6(a–f)
were also studied. The effect of different [Et3NH][HSO4] ionic liquid catalyst loads on the yield of
product and time required for completion of reaction were studied at various catalyst loads such
as 5, 10, 15 mol % and at various temperatures such as 70, 80, 90 and 100 ◦C, as shown in Table 3.
When 5 mol % of the catalyst was used at 90 ◦C the product 6a was obtained in 88% yield in 30 min.
When 10 mol % catalyst was used at the same temperature, compound 6a was obtained in 87% yield
in 30 min. When 15 mol % catalyst was used at 90 ◦C, compound 6a was obtained in 85% yield in
30 min. Therefore, considering 5 mol % as an efficient amount, the reaction was carried out at various
temperatures like 70 ◦C, 80 ◦C, 90 ◦C and 100 ◦C. At 5 mol % catalyst loading the use of the higher
(100 ◦C) or lower (70 ◦C, 80 ◦C) temperatures than 90 ◦C gave the compound 6a in reduced yields after
longer times, therefore, 5 mol % of the [Et3NH][HSO4] ionic liquid as catalyst and solvent was shown
to give the best yield (88%) in a short reaction time (30 min) at 90 ◦C (Entry 3 of Table 3). The recovery
and reusability of the catalyst in the synthesis of compound 6a was also investigated. The findings are
listed in Table 4; the recovered catalyst can be reused for at least four additional times in subsequent
reactions without any considerable decrease in its catalytic activity.
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Table 3. Effect of different reaction conditions on [Et3NH][HSO4] catalyzed synthesis of 6a.
Entry Temperature (◦C) Catalyst (mol %) Time (min) Yield (%)
1 70 5 48 75
2 80 5 42 80
3 90 5 30 88
5 100 5 30 85
6 90 10 30 87
7 90 15 30 85
Table 4. Reusability of [Et3NH][HSO4] catalyst for model reaction 6a.
Entry Run Time Yield
1 1 30 88
2 2 30 86
3 3 30 85
4 4 30 80
5 5 30 72
A total of six 4-(6-substituted-4-oxo-4H-chromen-3-yl)-6-methyl-2-thioxo/oxo-1,2,3,4-tetra-hydropyrimidine-
5-carbohydrazides 6(a–f) were synthesized according to the abovementioned green synthetic protocol.
The time required for the completion of reactions was around 20–35 min (monitored by TLC), and the
yields of the synthesized novel compounds were in the 80–95% range The structures of the synthesized
compounds were confirmed by IR, 1H-NMR, 13C-NMR, mass spectral analysis and elemental analysis.
2.2. Biological Activity
2.2.1. In Vitro Antibacterial Activity
All the synthesized compounds 4(a–f) and 6(a–f) were screened for their in vitro antibacterial
activity against Staphylococcus aureus (NCIM-2901), Escherichia coli 1411 (standard laboratory strains)
and Escherichia coli SM1411 (an acrAB deficient derivative of 1411). Minimum inhibitory concentration
(MIC100) values were determined using methods recommended by National Committee for Clinical
Laboratory Standards (NCCLS) [26,29–31]. Dimethyl sulfoxide (DMSO) was used as solvent control.
The results of the in vitro antibacterial activity are presented in Table 5. The compound 6c bearing a
fluoro group on the chromone ring and oxygen and –NHNH2 groups on the pyrimidine ring was
found to be the most potent antibacterial compound against E. coli 1411, E. coli SM1411 and S. aureus,
with MIC100 values of 14 µg/mL, 14 µg/mL and 32 µg/mL, respectively. The compound 4c was found
to be the most potent antibacterial compound among the synthesized derivatives against S. aureus,
with the MIC100 value 30 µg/mL.
Table 5. In vitro antibacterial activity of the synthesized compounds 4(a–f) and 6(a–f).
Compound IC50 (µM)
MIC100 a (µg/mL)
E. coli 1411 E. coli SM1411 S. aureus NCIM-2901
4a 158 46 40 64
4b 296 50 50 68
4c 155 38 34 30
4d 330 55 54 >200
4e 335 58 >60 >200
4f 280 48 44 72
6a 127 34 32 66
6b 124 34 34 76
6c 106 14 14 32
6d 111 16 18 40
6e 315 >60 58 156
6f >400 >60 >60 >200
D-Cycloserine 276 16 16 32
a Values are the average of three readings; E.coli 1411: Escherichia coli 1411, E.coli SM1411 Escherichia coli SM 1411;
S. aureus NCIM-2901: Staphylococcus aureus (NCIM-2901); MIC: Minimum inhibitory concentration; Bold value
indicates equipotent /nearness to values of standard drug D-Cycloserine.
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The compound 6d bearing a fluoro group on the chromone ring and –NHNH2 and sulphur
groups on the pyrimidine ring was found to be equipotent to the standard drug D-cycloserine against
S. aureus, with a MIC100 value of 32 µg/mL. The compounds 4d, 4e, 6e and 6f were found to be less
active against E. coli 1411, E. coli SM1411 and S. aureus.
2.2.2. In Vitro Antifungal Activity
The newly synthesized derivatives 4(a–f) and 6(a–f) were screened for their in vitro antifungal
activity against different yeast and filamentous fungal pathogens. Minimum inhibitory concentration
(MIC100) values for in vitro antifungal activity were determined by the methods recommended by
National Committee for Clinical Laboratory Standards (NCCLS) [26,29–31]. Miconazole was used as
standard drug. Dimethyl sulfoxide (DMSO) was used as solvent control. The MIC100 (µg/mL) of all
the tested compounds and that of the reference drug miconazole are listed in Table 6. Results from
Table 6 indicated that all the synthesized compounds showed good to moderate in vitro antifungal
activity against the tested fungal strains.
Table 6. In vitro antifungal activity of the synthesized compounds 4(a–f) and 6(a–f).
Compound
MIC 100 a (µg/mL)
C. alb. C. glab. F. oxy. A. fum. A. fla. A. nig. C. neo.
4a >100 >100 82 65 66 57 60
4b 64 66 58 60 66 52 55
4c 52 58 58 62 58 44 46
4d 34 38 36 36 20 20 24
4e 30 32 30 34 18 18 20
4f 46 44 48 55 34 34 30
6a 78 68 76 60 68 55 58
6b 64 60 54 58 60 48 50
6c 52 52 58 60 42 40 40
6d 44 40 44 52 30 28 28
6e 28 30 30 32 16 18 16
6f 24 25 28 33 15 16 15
Miconazole 25 25 25 35 12 12 12
a Values are the average of three readings; C. alb.: Candida albicans; C. glab.: Candida glabrata; F. oxy.: Fusarium
oxysporum; A. fum.: Aspergillus fumigates; A. nig.: Aspergillus niger; C. neo.: Cryptococcus neoformans; MIC100: Minimum
inhibitory concentration; Miconazole: Standard drug; Bold value indicates equipotent /nearness to values of
standard drug Miconazole.
The compounds 6f, 6e and 4e were found to be the most potent antifungal agents among the
synthesized derivatives. The compound 6f bearing a –OCH3 group on the chromone ring and a sulphur
group on the pyrimidine ring, was found to exhibit equipotent antifungal activity when compared
with the standard drug miconazole. Compound 6f had MIC100 values of 24 µg/mL for C. albicans,
25 µg/mL for C. glabrata, 28 µg/mL for F. oxysporum, 33 µg/mL for A. fumigates, 15 µg/mL for A. flavus,
16 µg/mL for A. niger and 15 µg/mL for C. neoformans. Compound 6e was found to be the second
most potent antifungal agent among the synthesized compounds, with MIC100 values 28 µg/mL for
C. albicans, 30 µg/mL for C. glabrata, 30 µg/mL for F. oxysporum, 32 µg/mL for A. fumigates, 16 µg/mL
for A. flavus, 18 µg/mL for A. niger and 16 µg/mL for C. neoformans. Compound 6f exhibited more
potent in vitro antifungal activity than the compounds 6b and 6d, which may be due to the presence of
the electron donating –OCH3 substituent on the chromone ring. The compounds 4a, 4b and 4c were
found to be the least active antifungal agents among the synthesized series.
From the structure activity relationship (SAR) it could be manifested that the nuclei such
as chromone and pyrimidine pharmacophores along with X = O/S are responsible for the
antimicrobial activity. It could be deduced from the structure activity relationships (SARs), in general
that the moderation on the chromone ring and the pyrimidine ring appreciably influenced the
antimicrobial activity. The compounds 6c with R1 = F group on the chromone ring and X = O
group and –NHNH2 group on the pyrimidine ring was found to be more potent antibacterial agents
than the standard drug D-cycloserine against all the tested bacterial strains. The compound 4c with
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R1 = F group on the chromone ring and X = O group and –OC2H5 group on the pyrimidine ring was
found to be a more potent antibacterial agent than the standard drug D-cycloserine against the S. aureus
bacterial strain. The compound 6d with R1 = F group on the chromone ring and X = S group and
–NHNH2 group on the pyrimidine ring was found to be equipotent to the standard drug D-cycloserine
against the E. coli bacterial strain. The compounds 4b, 4e, 4f, 6b, 6d and 6f with the sulphur group
on the pyrimidine ring were found to be more moderately active antibacterial agents than those with
oxygen groups on the pyrimidine ring 4a, 4c, 4d, 6a, 6c and 6e. Replacement of the –OC2H5 group
with a –NHNH2 group on the pyrimidine ring significantly increased the in vitro antifungal activity.
The compound 6f with the –OCH3 group on the chromone ring and NHNH2 and S group on the
pyrimidine ring was found to be the most active antifungal agent among the synthesized series against
all the tested fungal strains. The compound 4e (–OCH3 on the chromone ring and S group and –OC2H5
group on the pyrimidine ring) and compound 6e (–OCH3 on the chromone ring and S group and on
the pyrimidine ring) showed excellent in vitro antifungal activity against all the selected fungal strains.
The compounds 4b, 4e, 4f, 6b, 6d and 6f with the sulphur group on the pyrimidine ring were found to
be more active antifungal agents than those with oxygen group on the pyrimidine ring 4a, 4c, 4d, 6a,
6c and 6e. The chromone ring when substituted with an electron donating group such as R1 = OCH3
(4d, 4e, 6e and 6f) was found to show better antifungal activity than when substituted with an electron
withdrawing group like R1 = F (4c, 4f, 6c and 6d).
2.2.3. Ergosterol Extraction and Quantitation Assay
Considering that ergosterol is an important fungal cell membrane lipid, changes in its biosynthetic
pathway may also cause damage to the fungal cell, preventing growth in a way similar as azole
compounds such as miconazole, fluconazole, etc. do [36]. To reveal the antifungal mechanism of
the most potent synthesized compound 6f, its influence on the sterol composition on the C. albicans
membrane was monitored by analyzing the changes in the sterol composition in the cells of C. albicans
by U.V. analysis. The assay was performed at various concentrations of the most potent synthesized
compound 6f such as MIC/16, MIC/8, MIC/4, MIC/2 and MIC value to quantify the content of sterol
produced by C. albicans, as shown in Figure 1.
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extracted from fungal culture at the wavelengths of 230 nm, and 281.5 nm was analyzed and the 
results obtained are as shown in Figure 1 for compound 6f. Ergosterol and an intermediate of the 
metabolic pathway, ergosterol-24(28) dehydroergosterol (DHE), absorb energy at 281.5 nm, but only 
DHE shows an intense absorption at 230 nm. Changes in this absorption pattern are therefore 
Figure 1. UV spectrophoto etric sterol profile of C. albicans (NCIM3471) treated with, 0 (curve a),
1.5 (curve b), 3 (curve c), 6 (curve d), 12 (curve e) and 24 (curve f) µg/mL of synthesized compound 6f
and 25 (curve g) µg/mL of miconazole. Sterols were extracted from cells and spectral profiles between
240 and 300 nm were determined.
Curve “a” in Figure 1 represents the negative control (no compound). The absorption of sterols
extracted from fungal culture at the wavelengths of 230 nm, and 281.5 nm was analyzed and the
results obtained are as shown in Figure 1 for compound 6f. Ergosterol and n intermediate of the
metabolic pathway, ergosterol-24(28) dehydroergosterol (DHE), absorb energy at 281.5 nm, but only
DHE shows an intense absorption at 230 nm. Changes in this absorption pattern are therefore indicative
of interference in the synthetic pathway of ergosterol [26,40]. There was a change in the absorption
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pattern for the synthesized compound 6f as shown in Figure 1, which proves that the synthesized
compound 6f inhibits ergosterol biosynthesis by inhibiting the enzyme cytochrome P450 lanosterol 14
α-demethylase of C. albicans.
Curve “a” shows an intense ergosterol peak at 281.5 nm signifying the presence of this compound.
Curve “g” in Figure 1 indicates the inhibition of ergosterol by miconazole (standard drug) at its MIC
value. As the concentration of the synthesized compound 6f increases the intensity of the ergosterol
peak at 281.5 nm decreases, which indicates a decrease in the concentration of ergosterol in the
culture medium. In Figure 2 there is almost a flat peak of compound 6f at its MIC100 value, which is
almost similar to that of standard drug miconazole at its MIC100 value. These results suggest that the
compound 6f might inhibit the important enzyme in fungus, i.e., lanosterol 14α-demethylase, in a
similar manner to that accepted mechanism of the standard drug miconazole.
2.2.4. D-Alanine-D-alanine ligase (Ddl) Enzyme Assay
The key enzyme involved in the peptidoglycan biosynthesis is D-alanine-D-alanine ligase (Ddl),
making it an important target for drug discovery. Inhibition of DdlB as an essential enzyme in either
Gram-positive or Gram-negative organisms leads to the loss of cell shape and integrity followed by
bacterial death. The synthesized derivatives 4(a–f) and 6(a–f) were tested for their inhibitory activity
on DdlB from E.coli. The results are presented as IC50 values. The compounds 4a, 4c, 6a, 6b, 6c and 6d
were found to be better DdlB enzyme inhibitors than the standard drug D-cycloserine. The compound
6c bearing R1 = fluoro on the chromone ring and X = O and –NHNH2 groups on the pyrimidine ring,
was found to be the most potent DdlB enzyme inhibitor among the synthesized series. The compounds




Docking is an effective and reliable approach to simulate the probable binding mode of ligands
and proteins. Recently, coumarin derivatives have been reported to inhibit cytochrome P450 lanosterol
14α-demethylase (CYP51) [35]. Based on literature reports [36] and the antifungal activity exhibited by
the synthesized compounds, molecular docking studies were performed in the active site of cytochrome
P450 lanosterol 14α-demethylase enzyme of C. albicans [38] to understand its mechanism of action.
In silico approaches like molecular docking have become very useful to identify potential targets for
different ligands and they are associated with the thermodynamic interactions with the target enzyme
governing the inhibition of the target microorganism [26]. The docking scores of the synthesized
compounds 4(a–f) and 6(a–f) are presented in Table 7.
Table 7. The docking scores of the synthesized compounds 4(a–f) and 6(a–f) for cytochrome P450
lanosterol 14α-demethylase enzyme of C. albicans.
Compound Docking Score Compound Docking Score
4a −5.88 6a −5.30
4b −6.20 6b −5.43
4c −6.96 6c −7.01
4d −6.99 6d −7.21
4e −7.00 6e −6.96
4f −6.80 6f −7.24
Miconazole −7.33
The docking data results revealed that the synthesized compounds were held in the active pocket
by forming various interactions with the cytochrome P450 lanosterol 14α-demethylase of C. albicans
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such as hydrogen and hydrophobic interactions. The docking score of compound 6f i.e −7.24 was
found to be almost similar to that of standard drug miconazole i.e., −7.33. Figure 2 represents the
docking pose of compound 6f in the active pocket of cytochrome P450 lanosterol 14α-demethylase of
C. albicans and it can be seen that the NH2 group of compound 6f forms a hydrogen bond interaction
with the HEM 500 and TYR 173. The phenyl ring containing a methoxy group fits well into the
hydrophobic pocket of the enzyme.
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Figure 2. The docking pose of compound 6f in the active pocket of cytochrome P450 lanosterol
14α-demethylase of C. albicans. (Light orange colored structure represents the heme co-factor, Pink bond
represents the hydrogen bonding between ligand and receptor, Purple colored structure represents
the molecule).
On the basis of the in vit o an ifungal activity, ergosterol ex raction and quantitation assay and
molecular do king study resu t, it was established th t the synthesized compounds could inhibit the
enzyme cytochrome P450 lanosterol 14α-demethylase of C. albicans. From the docking score data nd
the in vitro antifungal activity results it can be concluded that the compounds 4e, 6e and 6f have good
potential to inhibit the enzyme cytochrome P450 lanosterol 14α-demethylase of C. albicans.
Inhibition of Ddl in bacteria by drugs hinders the growth of bacteria, which makes this enzyme
an irresistible and important target for the discovery of novel antimicrobial drug. Hence, molecular
docking was performed against E. coli DdlB (PDB entry: 1IOV). The docking scores of the synthesized
compounds 4(a–f) and 6(a–f) are presented in Table 8. The docking results indicated that the
compounds were held in the active pocket by combination of various hydrogen and hydrophobic
interactions with DdlB enzyme. The docking results revealed that, the highest binding compound to
DdlB enzyme was compound 6c with a G-Score of −6.71.
Table 8. Docking score of the synthesized compounds 4(a–f) and 6(a–f) for DdlB enzyme.
Compound Docking Score Compound Docking Score
4a −6.00 6a −6.48
4b −5.66 6b −6.33
4c −6.56 6c −6.71
4d −2.46 6d −6.41
4e −3.00 6e −1.81
4f −3.76 6f −0.89
D-Cycloserine −6.22
Fr m he in vitro antibact rial data, D-alanine-D-alanine enzyme assay study and molecular
docking study it was found that the synthesized compounds 6a, 6b, 6c and 6d are capable of inhibiting
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the DdlB enzyme. Figure 3 represents the docking pose of compound 6c into the active pocket of
DdlB enzyme. The compound shows a hydrogen bond interaction with amino acid residue LYS159.Molecules 2018, 23(2), 440; doi: 10.3390/molecules23020440  11 of 22 
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Figure 3. The docking pose of compound 6c into the active pocket of DdlB enzyme. (Pink bond
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2.3.2. In Silico Absorption, Distribution, Metabolism, Elimination and Toxicity (ADMET) Prediction
2D structures of all the synthesized ethyl 4-(6-substituted-4-oxo-4H-chromen-3-yl)-
6-methyl-2-thioxo/oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate and 4-(6-substituted-4-oxo-4H-
chromen-3-yl)- -methyl-2-thioxo/oxo-1,2,3,4-tetrahydropyrim dine-5-carbohydrazide derivatives
4(a–f) an 6(a–f) were s bje ted to in silico pharmacokin tic scree ing using Qikpr p v. 3.5
(Schro inger LLC) to study compliance with the Lipinski rule of fiv and Jorgensen’s rule of ree.
Understanding of in silico physicochemical harmacokinetic parameters is imperative to predict the
oral bioavailability of the synthesized compounds 4(a–f) and 6(a–f). It was contemplated that none of
the synthesized compounds 4(a–f) and 6(a–f) violated Lipinski rule of 5 and Jorgensen’s rule of three,
as shown in Tables 9 and 10, respectively. The synthesized compounds 4(a–f) and 6(a–f) showed polar
surface area (PSA) value ranges between 96.6 to 160.3 Å, as shown in Table 9, which suggests the good
cell permeability properties of the synthesized compounds [41].
Table 9. In silico physicochemical pharmacokinetic parameters important for good bioavailability
according to Lipinski rule of 5 for the synthesized compoun s 4(a–f) and 6(a–f).
Compound M.W a Log P o/w
b








4a 328.3 2.7 4.5 0 117.8 0
4b 344.3 3.4 5.0 0 96.6 0
4c 346.3 3.0 4.5 0 118.0 0
4d 358.3 2.8 5.2 0 125.9 0
4e 374.4 3.5 5.7 0 104.2 0
4f 362.3 3.6 5.0 0 97.2 0
6a 314.1 1.2 5.5 3 149.3 0
6b 330.3 1.9 6.0 3 128.5 0
6c 332.2 1.4 5.5 3 150.0 0
6d 348.3 2.0 6.0 3 130.4 0
6e 344.3 1.9 6.2 3 160.3 0
6f 360.3 1.9 6.7 3 137.5 0
Miconazole 402.1 6.6 5.0 1 67.1 1
a Molecular weight of the molecule; b Predicted octanol–water partition coefficient (log Po/w) (−2.0 to 6.5);
c n-ON number of ydrogen b nd acceptors ≤10; d n-OHNH number of hydrogen bonds donors ≤5; e Pola surface
area (PSA) (7.0–200.0); Miconazole: Standard drug.
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All the synthesized compounds 4(a–f) and 6(a–f) have Log S values within the desired range
(−5.11–4.04) as shown in Table 10. The synthesized compounds showed BIPCaco-2 value ranges between
48.37 to 1137.55, which indicates good in silico intestinal absorption. The synthesized compounds
exhibited MDCK values which range from 18.73 to 2820.05, indicating good in silico oral absorption [42].
The synthesized compounds showed Log Khsa values ranging between −0.01 to 0.24, as shown in
Table 10, which is an indication that a significant proportion of the compounds are likely to circulate
freely in the blood stream and hence reach the target sites. The most active antimicrobial compounds
6c, 6e and 6f showed 69.97%, 64.09% and 79.39% absorption, respectively. The HERG K+ channel,
which is best known for its contribution to the electrical activity of the heart that coordinates the
heart’s beating, appears to be the molecular target responsible for the cardiac toxicity of a wide range
of therapeutic drugs [43]. Thus, HERG K+ channel blockers are potentially toxic and the predicted
IC50 values often provide reasonable predictions for cardiac toxicity of drugs in the early stages of
drug discovery [26,44]. From the Log HERG values in Table 10 it is observed that all the synthesized
compounds 4(a–f) and 6(a–f) are non-toxic in nature.
Table 10. In silico physicochemical pharmacokinetic parameters important for good oral bioavailability









(−1.5 to 1.2) % ABS
e Log HERG f
(Below −5) Toxicity
4a −4.33 271.70 120.96 0.24 86.50 −4.88 N
4b −4.72 1032.02 1427.30 0.19 100 −4.94 N
4c −4.92 254.65 203.96 0.31 87.66 −4.98 N
4d −4.62 246.14 108.71 0.24 86.28 −4.98 N
4e −5.00 1137.55 1583.83 0.19 100 −5.01 N
4f −5.11 1121.26 2820.05 0.23 100 −4.90 N
6a −3.81 86.72 35.20 −0.03 69.11 −4.75 N
6b −4.39 265.39 328.59 −0.03 81.81 −5.04 N
6c −3.98 82.41 60.29 0 69.97 −4.69 N
6d −4.60 190.52 415.33 0 79.95 −4.91 N
6e −4.04 48.37 18.73 −0.01 64.09 −4.83 N
6f −4.58 195.06 235.15 −0.01 79.39 −4.97 N
Miconazole −5.80 4747.2 10000 0.83 100 −5.5 N
a Logarithm of Aqueous solubility (Log S) (−6 to 0.5); b Predicted apparent Caco-2 cell permeability, in nm/sec
(BIPCaco-2) (<25 poor, >500 good);
c Predicted apparent MDCK cell permeability in nm/sec (MDCK) (<25 poor,
>500 good); d Logarithm of predicted binding constant to human serum albumin (log Khsa) (−1.5 to 1.2); e Percentage
human oral absorption (% ABS) (>80% is high, <25% is poor); f Predicted IC50 value for blockage of HERG K+
channels (Log HERG) (below −5); N: Non-toxic.
2.4. In Vitro Cytotoxicity Study
Toxicity scrutiny of synthesized compounds at the early phase of research paves the way to
clinical trials and reduces the failure of potential therapeutics at later stages of clinical trials [24].
To scrutinize the safety and selectivity of antimicrobial activity of the synthesized compounds,
the compounds 6c and 6f were appraised for their toxicity against HeLa (a human cervical cancer
cell line) and PC-3 (human prostate cancer cell line) by the Sulforhodamine B (SRB) assay using
adriamycin as a standard drug [26,45]. The cytotoxic effect of the synthesized compounds 6c and
6f was checked on cancer cell lines using the concentration range between 80 and 0.55 µg/mL,
to determine the 50% growth inhibition (GI50). The results obtained are summarized in Table 11.
The results indicate that in cytotoxicity studies, the most active synthesized compounds 6c and 6f
can be considered as antimicrobial agent leads due to their lack of cell toxicity against HeLa at the
maximum concentration evaluated. Figure 4 represents that cell inhibition did not occur even up to
80 µg/mL concentration of the synthesized compounds 6c and 6f and hence they can be considered as
non-toxic in nature and selective in their antimicrobial activity.
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HeLa (human cervical cancer cell line); PC-3 (human prostate cancer cell line); adriamycin: standard drug.
2.5. In Vivo Acute Oral Toxicity Study and Behavioral Study
Animals treated with the newly synthesized compounds 6c and 6f were free of any toxicity as per
acceptable range given by the OECD guideline No. 425 and no mortality was found up to 2000 mg/kg,
which indicated that the lethal dose of the compounds is above 2000 mg/kg body weight in mice and
that the compounds 6c and 6f can be considered to be safe and could be developed in the future as
good antimicrobial agents. The in vivo acute oral toxicity and gross behavioral study results of the
newly synthesized compounds 6c and 6f are as listed in Table 12 [26].
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3. Materials and Methods
3.1. General Information
All the reactions were performed in oven-dried glassware. All reagents and solvents were used
as obtained from the supplier or recrystallized/redistilled unless otherwise noted. The purity of the
synthesized compounds was monitored by ascending thin layer chromatography (TLC) on silica gel-G
(Merck, Darmstadt, Germany) coated aluminum plates, visualized by iodine vapor. Melting points
were determined in open capillary tubes and are uncorrected. Infrared (IR) spectra were recorded
on a PS 4000 FTIR instrument (JASCO, Tokyo, Japan) using KBr pellets. Elemental analyses (C, H,
and N) were done with a FLASHEA 112 analyzer (Shimadzu, Mumbai, Maharashtra, India) and all
analyses were consistent (within 0.4%) with theoretical values. The 1H-NMR and 13C-NMR spectra of
synthesized compounds were recorded on an Avance II 400 NMR spectrometer (Bruker, Billerica, MA,
USA) at 400/100 MHz frequency in DMSO-d6 or CDCl3 and using TMS as internal standard (chemical
shift δ values are expressed in ppm). Mass spectra were scanned on a Micromass Q-Tof system (Waters,
Manchester, UK) [26].
3.2. Synthesis of Ethyl 4-(6-Substituted-4-oxo-4H-chromen-3-yl)-6-methyl-2-thioxo/oxo-1,2,3,4-tetrahydro-
pyrimidine-5-carboxylate Derivatives 4(a–f)
A mixture of substituted 4-oxo-4H-chromene-3-carbaldehydes 1(a–c) (1 mmol), ethyl acetoacetate
(2) (1 mmol), urea/thiourea (3) (1 mmol) and [Et3NH][HSO4] (15 mol %) was refluxed under
solvent-free conditions at 100 ◦C for the required time while the reactions were monitored by TLC.
After completion of the reaction, the reaction mixture was poured into crushed ice and stirred for
5 min. The solid obtained was filtered, washed with cold water and then recrystallized from ethanol
to afford the pure product. The ionic liquid present in the filtrate was recovered and was used for
other reactions.
Ethyl 6-methyl-2-oxo-4-(4-oxo-4H-chromen-3-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate 4a.
Yield 95%; M.P.: 270–272 ◦C; IR (KBr vmax in cm−1): 3238 (N–H stretching), 3005 (C–H stretching),
2900 (–CH3 stretching), 2815 (alkyl CH stretching), 1746 (C=O stretching), 1601 (C=C stretching),
1454 (CH bending of CH2), 1356 (C–N stretching), 1002 (–O– stretching); 1H-NMR (DMSO-d6,
δH ppm): 1.14 (t, J = 7.10 Hz, 3 H, CH3), 2.28 (s, 3 H, CH3), 4.05 (q, J = 7.04 Hz, 2 H, CH2), 4.72 (d,
J = 1.49 Hz, 1H, CH), 7.41–7.59 (m, 3H, aromatic), 7.75 (s, 1H, NH), 8.05 (s, 1H, aromatic), 8.10 (d,
J = 1.44 Hz, 1H, aromatic), 9.12 (s, 1H, NH); 13C-NMR (DMSO-d6, δC ppm): 14.45, 18.51, 45.91, 61.37,
101.94, 118.07, 121.61, 123.87, 126.27, 126.68, 133.85, 149.33, 150.72, 155.65, 155.77, 167.37, 172.17; MS:
m/z: 329.21 [M + 1]+; Anal. Calcd. for C17H16N2O5: C, 62.19; H, 4.91; N, 8.53. Found: C, 62.20; H, 4.93;
N, 8.50.
Ethyl 6-methyl-4-(4-oxo-4H-chromen-3-yl)-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate 4b.
Yield 87%; M.P.: 210–212 ◦C; IR (KBr vmax in cm−1): 3235 (N–H stretching), 3005 (C–H stretching),
2905 (–CH3 stretching), 2815 (CH alkyl stretching), 1600 (C=C stretching), 1454 (CH bending of CH2),
1360 (C–N stretching), 1140 (C=S stretching), 1002 (–O– stretching); 1H-NMR (DMSO-d6, δH ppm):
1.17 (t, J = 7.10 Hz, 3 H, CH3), 2.29 (s, 3 H, CH3), 4.74 (d, J = 1.49 Hz, 1H, CH), 7.47–7.74 (m, 3H,
aromatic), 8.03 (s, 1H, NH), 8.06 (s, 1H, aromatic), 8.12 (d, J = 1.44 Hz, 1H, aromatic), 8.89 (s, 1H, NH);
13C-NMR (DMSO-d6, δC ppm): 14.50, 18.44, 50.62, 61.77, 106.24, 118.71, 121.32, 123.99, 126.12, 133.91,
150.11, 155.60, 160.39, 167.33, 171.94, 177.89; MS: m/z: 345.01 [M + 1]+; Anal. Calcd. for C17H16N2O4S:
C, 59.29; H, 4.68; N, 8.13. Found: C, 59.31; H, 4.69; N, 8.10.
Ethyl 4-(6-fluoro-4-oxo-4H-chromen-3-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate 4c.
Yield 92%; M.P.: 200–202 ◦C; IR (KBr vmax in cm−1): 3230 (N–H stretching), 3000 (C–H stretching),
2900 (–CH3 stretching), 2815 (CH alkyl stretching), 1745 (C=O stretching), 1600 (C=C stretching),
1454 (CH bending of CH2), 1364 (C–N stretching), 1002 (–O– stretching); 1H-NMR (DMSO-d6, δH ppm):
1.15 (t, J = 7.10 Hz, 3 H, CH3), 2.29 (s, J = 2.11 Hz, 3 H, CH3), 4.09 (q, J = 7.04 Hz, 2 H, CH2), 4.74 (d,
J = 1.51 Hz, 1H, CH), 6.91–7.11 (m, 2 H, aromatic), 7.43 (s, 1 H, NH), 7.74 (d, J = 2.93 Hz, 1 H, aromatic)
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8.06 (s, 1 H, aromatic), 9.13 (s, 1H, NH); 13C-NMR (DMSO-d6, δC ppm): 14.22, 18.11, 45.51, 61.70,
101.99, 111.52, 118.71, 119.23, 122.00, 126.88, 149.14, 150.79, 155.13, 156.11, 164.19, 167.19, 172.10; MS:
m/z: 347.11 [M + 1]+; Anal. Calcd. for C17H15FN2O5: C, 58.96; H, 4.37; N, 8.09. Found: C, 58.99; H,
4.39; N, 8.04.
Ethyl 4-(6-methoxy-4-oxo-4H-chromen-3-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate 4d.
Yield 88%; M.P.: 230–232 ◦C; IR (KBr vmax in cm−1): 3238 (N–H stretching), 3005 (C–H stretching),
2900 (–CH3 stretching), 2845 (–OCH3 stretching), 2815 (alkyl CH stretching), 1742 (C=O stretching),
1600 (C=C stretching), 1454 (CH bending of CH2), 1362 (C–N stretching), 1002 (–O– stretching);
1H-NMR (DMSO-d6, δH ppm): 1.17 (t, J = 7.10 Hz, 3 H, CH3), 2.29 (s, J = 2.11 Hz, 3 H, CH3), 3.80 (s,
3 H, O CH3), 4.10 (q, J = 7.04 Hz, 2 H, CH2) 4.74 (d, J = 1.51 Hz, 1H, CH), 7.37 (d, J = 8.90 Hz, 1H),
7.42 (s, 1H, NH), 7.48–7.52 (m, 2 H), 8.06 (s, 1H, aromatic), 9.13 (s, 1 H, NH); 13C-NMR (DMSO-d6,
δC ppm): 14.45, 18.51, 45.91, 55.08, 61.37, 101.94, 107.44, 117.98, 119.35, 122.42, 149.33, 150.72, 152.63,
155.65, 156.18, 167.37, 171.94; MS: m/z: 359.53 [M + 1]+; Anal. Calcd. for C18H18N2O6: C, 60.33; H, 5.06;
N, 7.82. Found: C, 60.35; H, 5.09; N, 7.80.
Ethyl 4-(6-methoxy-4-oxo-4H-chromen-3-yl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate 4e.
Yield 86%; M.P.: 222–224 ◦C; IR (KBr vmax in cm−1): 3235 (N–H stretching), 3008 (C–H stretching),
2908 (–CH3 stretching), 2845 (–OCH3 stretching), 2813 (alkyl CH stretching), 1740 (C=O stretching),
1600 (C=C stretching), 1454 (CH bending of CH2), 1360 (C–N stretching), 1148 (C=S stretching),
1002 (–O– stretching); 1H-NMR (DMSO-d6, δH ppm): 1.17 (t, J = 7.10 Hz, 3 H, CH3), 2.29 (s, 3 H, CH3),
3.80 (s, 3 H, O CH3), 4.11 (q, J = 7.04 Hz, 2 H, CH2), 4.73 (d, J = 1.49 Hz, 1 H), 7.37 (d, J = 8.90 Hz, 1 H),
7.36 (s, 1 H, NH), 7.48–8.08 (m, 3 H), 8.89 (s, 1 H, NH); 13C-NMR (DMSO-d6, δC ppm): 14.45, 18.51,
49.08, 55.80, 61.37, 104.43, 107.44, 117.98, 119.35, 122.42, 126.68, 149.33, 152.63, 154.52, 156.18, 167.37,
171.94, 177.89; MS: m/z: 375.17 [M + 1]+; Anal. Calcd. for C18H18N2O5S: C, 57.74; H, 4.85; N, 7.48.
Found: C, 57.77; H, 4.86; N, 7.46.
Ethyl 4-(6-fluoro-4-oxo-4H-chromen-3-yl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate 4f.
Yield 92%; M.P.: 228–230 ◦C; IR (KBr vmax in cm−1): 3230 (N–H stretching), 3000 (C–H stretching),
2910 (–CH3 stretching), 2810 (alkyl CH stretching), 1742 (C=O stretching), 1605 (C=C stretching),
1450 (CH bending of CH2), 1360 (C–N stretching), 1140 (C=S stretching), 1005 (–O– stretching);
1H-NMR (DMSO-d6, δH ppm): 1.15 (t, J = 7.10 Hz, 3 H, CH3), 2.29 (s, 3 H, CH3), 4.11 (q, J = 7.04
Hz, 2 H, CH2), 4.73 (d, J = 1.49 Hz, 1 H, CH), 6.91–7.74 (m, 3 H, aromatic), 7.76 (s, 1 H, NH), 8.08 (s,
1 H, aromatic), 8.89 (s, 1 H, NH); 13C-NMR (DMSO-d6, δC ppm): 14.44, 18.46, 50.66, 61.79, 106.33,
111.50, 118.73, 119.31, 122.18, 126.89, 149.15, 152.36, 160.19, 162.58, 167.79, 171.96, 177.88; MS: m/z:
363.15 [M + 1]+; Anal. Calcd. for C17H15FN2O4S: C, 56.35; H, 4.17; N, 7.73. Found: C, 56.37; H, 4.19;
N, 7.70.
3.3. Synthesis of 4-(6-Substituted-4-oxo-4H-chromen-3-yl)-6-methyl-2-thioxo/oxo-1,2,3,4-tetrahydro-
pyrimidine-5-carbohydrazide Derivatives 6(a–f)
A mixture of ethyl4-(6-substituted-4-oxo-4H-chromen-3-yl)-6-methyl-2-thioxo/oxo-1,2,3,4-
tetrahydropyrimidine-5-carboxylate derivative 4(a–f) (1 mmol), hydrazine hydrate (5) (1.2 mmol)
and [Et3NH][HSO4] (5 mol %) was refluxed under solvent-free conditions at 90 ◦C for the required
time, while reaction completion was monitored by TLC. After completion of the reaction, the reaction
mixture was poured into crushed ice and stirred for 5 min. The solid obtained was filtered, washed
with cold water and then recrystallized from ethanol to afford the pure product. The ionic liquid
present in the filtrate was recovered and was used for other reactions.
6-Methyl-2-oxo-4-(4-oxo-4H-chromen-3-yl)-1,2,3,4-tetrahydropyrimidine-5-carbohydrazide 6a. Yield 88%;
M.P.: 256–258 ◦C; IR (KBr vmax in cm−1): 3520 (NH2 stretching), 3450 (N–H stretching), 3000 (C–H
stretching), 2900 (–CH3 stretching), 1742 (C=O stretching), 1605 (C=C stretching), 1368 (C–N stretching),
1005 (–O– stretching); 1H-NMR (DMSO-d6, δH ppm): 2.03 (s, 3H, CH3), 3.13 (s, 2 H, NH2), 4.74 (d,
J = 1.51 Hz, 1H, CH), 7.08 (s, 1 H, NH), 7.42 (s, 1H, NH), 7.47–8.13 (m, 5H, aromatic), 9.39 (s, 1 H, NH);
13C-NMR (DMSO-d6, δC ppm): 18.49, 46.11, 102.31, 118.71, 121.61, 123.44, 126.23, 126.85, 133.88, 149.45,
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150.71, 155.36, 159.17, 168.62, 172.49; MS: m/z: 315.25 [M + 1]+; Anal. Calcd. for C15H14N4O4: C, 57.32;
H, 4.49; N, 17.83. Found: C, 57.32; H, 4.49; N, 17.83.
6-Methyl-4-(4-oxo-4H-chromen-3-yl)-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carbohydrazide 6b. Yield 88%;
M.P.: 198–200 ◦C; IR (KBr vmax in cm−1): 3515 (–NH2 stretching), 3450 (N–H stretching), 3000 (C–H
stretching), 2908 (–CH3 stretching), 1742 (C=O stretching), 1600 (C=C stretching), 1360 (C–N stretching),
1145 (C=S stretching), 1002 (–O– stretching); 1H-NMR (DMSO-d6, δH ppm): 2.26 (s, 3 H, CH3), 3.13 (s,
2H, NH2), 4.74 (d, J = 1.49 Hz, 1 H, CH), 7.08 (s, 1 H, NH), 7.47 (s, 1 H, NH), 7.59–8.13 (m, 5 H, aromatic),
8.89 (s, 1H, NH); 13C-NMR (DMSO-d6, δC ppm): 18.97, 51.16, 106.11, 118.23, 121.14, 123.43, 126.28,
126.81, 133.69, 150.11, 155.49, 160.19, 168.66, 172.32, 177.80; MS: m/z: 331.29 [M + 1]+; Anal. Calcd. for
C15H14N4O3S: C, 54.53; H, 4.27; N, 16.96. Found: C, 54.55; H, 4.29; N, 16.93.
4-(6-Fluoro-4-oxo-4H-chromen-3-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carbohydrazide 6c.
Yield 95%; M.P.: 210–212 ◦C; IR (KBr vmax in cm−1): 3510 (NH2 stretching), 3455 (N–H stretching),
3000 (C–H stretching), 2910 (–CH3 stretching), 1742 (C=O stretching), 1605 (C=C stretching), 1365 (C–N
stretching), 1005 (–O– stretching); 1H-NMR (DMSO-d6, δH ppm): 2.03 (s, 3 H, CH3), 3.13 (s, 2H, NH2),
4.74 (d, J = 1.51 Hz, 1 H, CH), 6.91 (d, J = 8.93 Hz, 1H), 7.08 (s, 1H, NH), 7.10–8.06 (m, 4 H, aromatic),
9.39 (s, 1H, NH); 13C-NMR (DMSO-d6, δC ppm): 18.26, 46.83, 106.12, 109.11, 118.36, 121.33, 123.39,
126.10, 147.77, 150.18, 155.60, 155.99, 162.45, 168.20, 172.45; MS: m/z: 333.55 [M + 1]+; Anal. Calcd. for
C15H13FN4O4: C, 54.22; H, 3.94; N, 16.86. Found: C, 54.25; H, 3.96; N, 16.83.
4-(6-Fluoro-4-oxo-4H-chromen-3-yl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carbohydrazide 6d.
Yield 90%; M.P.: 146–148 ◦C; IR (KBr vmax in cm−1): 3512 (NH2 stretching), 3458 (N–H stretching),
3000 (C–H stretching), 2912 (–CH3 stretching), 1742 (C=O stretching), 1605 (C=C stretching), 1360 (C–N
stretching), 1140 (C=S stretching), 1005 (–O– stretching); 1H-NMR (DMSO-d6, δH ppm): 2.27 (s, 3H,
CH3), 3.14 (s, 2H, NH2), 4.74 (d, J = 1.49 Hz, 1H, CH), 6.92 (d, J = 8.93 Hz, 1H), 7.09 (s, 1H, NH),
7.11–8.09 (m, 4H, aromatic), 8.90 (s, 1 H, NH); 13C-NMR (DMSO-d6, δC ppm): 18.10, 52.61, 106.21,
109.14, 118.24, 121.39, 123.41, 126.52, 150.19, 155.62, 160.41, 162.56, 168.21, 171.96, 177.81; MS: m/z:
349.72 [M + 1]+; Anal. Calcd. for C15H13FN4O3S: C, 54.22; H, 3.94; N, 16.86. Found: C, 54.27; H, 3.99;
N, 16.80.
4-(6-Methoxy-4-oxo-4H-chromen-3-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carbohydrazide 6e.
Yield 82%; M.P.: 208–210 ◦C; IR (KBr vmax in cm−1): 3520 (NH2 stretching), 3452 (N–H stretching),
3000 (C–H stretching), 2905 (–CH3 stretching), 2845 (–OCH3 stretching), 1742 (C=O stretching),
1605 (C=C stretching), 1362 (C–N stretching), 1005 (–O– stretching); 1H-NMR (DMSO-d6, δH ppm):
2.03 (s, 3H, CH3), 3.13 (s, 2H, NH2), 3.80 (s, 3 H, OCH3), 4.74 (d, J = 1.51 Hz, 1 H), 7.08 (s, 1H, NH),
7.37–8.06 (m, 5 H, aromatic), 9.39 (s, 1H, NH); 13C-NMR (DMSO-d6, δC ppm): 18.92, 46.48, 56.82, 106.66,
109.11, 118.24, 121.48, 123.49, 125.76, 147.41, 150.62, 155.12, 156.30, 168.61, 172.27; MS: m/z: 345.02
[M + 1]+; Anal. Calcd. for C16H16N4O5: C, 55.81; H, 4.68; N, 16.27. Found: C, 55.84; H, 4.69; N, 16.25.
4-(6-Methoxy-4-oxo-4H-chromen-3-yl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carbohydrazide 6f.
Yield 80%; M.P.: 158–160 ◦C; IR (KBr vmax in cm−1): 3522 (NH2 stretching), 3455 (N–H stretching),
3000 (C–H stretching), 2910 (–CH3 stretching), 2845 (–OCH3 stretching), 1742 (C=O stretching),
1605 (C=C stretching), 1360 (C–N stretching), 1146 (C=S stretching), 1005 (–O– stretching); 1H-NMR
(DMSO-d6, δH ppm): 2.26 (s, 3H, CH3), 3.13 (s, 2H, NH2), 3.80 (s, 3 H, OCH3), 4.74 (d, J = 1.49 Hz, 1 H),
7.08 (s, 1H, NH), 7.37–8.08 (m, 5H, aromatic), 8.89 (s, 1H, NH); 13C-NMR (DMSO-d6, δC ppm): 18.90,
51.50, 105.66, 106.41, 118.90, 121.71, 123.44, 126.47, 150.53, 150.66, 156.30, 160.31, 168.22, 171.96, 177.98;
MS: m/z: 361.10 [M + 1]+; Anal. Calcd. for C16H16N4O4S: C, 53.32; H, 4.47; N, 15.55. Found: C, 53.35;
H, 4.49; N, 15.51.
3.4. Biological Activity Assays
3.4.1. In Vitro Antibacterial Activity
All the synthesized compounds 4(a–f) and 6(a–f) were screened for their in vitro antibacterial
activity against Staphylococcus aureus (NCIM-2901) and Escherichia coli 1411 (standard laboratory strains)
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and Escherichia coli SM1411 (an acrAB deficient derivative of 1411). Minimum inhibitory concentration
(MIC100) values were determined using the method recommended by National Committee for Clinical
Laboratory Standards (NCCLS). In vitro antibacterial activities of the synthesized compounds 4(a–f)
and 6(a–f) were tested in Nutrient Broth (NB) for Bacteria by the two fold serial dilution method.
Seeded broth (broth containing microbial spores) was prepared in NB from 24 h old bacterial cultures
on nutrient agar (Hi-media) at 37 ± 1 ◦C. The bacterial suspension was adjusted with sterile saline to a
concentration of 1 × 10−4–10−5 C.F.U. The synthesized compounds and standard drug D-cycloserine
were prepared by two fold serial dilutions to obtain the required concentrations. The tubes were
incubated in BOD incubators at 37 ± 1 ◦C for bacteria. The MICs were recorded by visual observations
after 24 h (for bacteria) of incubation [26,29–31].
3.4.2. D-Alanine-D-alanine ligase (DdlB) Enzyme Inhibition Study
The D-Ala-adding activity of DdlB ligase was monitored by the detection of orthophosphate
generated during the reaction based on the colorimetric malachite green method described by
Walsh et al. [46]. Assays were performed at 37 ◦C in a mixture (final volume: 50 µL) containing
38.5 mM Hepes, pH 8.0, 3.25 mMMgCl2, 6.5 mM (NH4)2SO4, 700 µM D-Ala, 500 µM ATP, purified
DdlB (diluted in 20 mM HEPES, pH 7.2, and 1 mM dithiothreitol) and the test compound (IC50 values
were determined for a range of inhibitor concentrations). All the compounds were soluble in the
assay mixture containing 5% DMSO. After 30 min of incubation, 100 µL Biomol reagent was added.
After 5 min, absorbance was read at 650 nm. Residual activity was calculated with respect to a similar
assay without inhibitor. To exclude possible non-specific (promiscuous) inhibitors, representative
compounds 4(a–f) and 6(a–f) were also tested in the presence of Tween (0.003%), Triton X-114 (0.005%),
and SDS (420 µM), as described by McGovern et al. [47,48]. No significant differences were found
when compared to measurements without detergents [49].
3.4.3. In Vitro Antifungal Activity
In vitro antifungal activity was determined as per CLSI (formerly, NCCLS) guidelines [29–31].
The synthesized compounds 4(a–f), 6(a–f) and the standard drug miconazole were dissolved in DMSO
solvent. The medium yeast nitrogen base was dissolved in phosphate buffer pH 7 and it was autoclaved
at 110 ◦C for 10 min. With each set a growth control without the antifungal agent and solvent control
DMSO were included. The fungal strains were freshly sub cultured on to Sabouraud dextrose agar
(SDA) and incubated at 25 ◦C for 72 h. The fungal cells were suspended in sterile distilled water and
diluted to get 105 cells/mL. Further, ten microlitres of the standardized suspension was inoculated
onto the control plates and the media incorporated with the antifungal agents. The inoculated plates
were incubated at 25 ◦C for 48 h. The readings were taken at the end of 48 h and 72 h. The MIC was the
lowest concentration of drug preventing growth of macroscopically visible colonies on drug containing
plates when there was visible growth on the drug free control plates [26].
3.4.4. Ergosterol Extraction and Quantitation Assay
A single Candida albicans (NCIM-3471) colony from an overnight Sabouraud dextrose agar
plate culture was used to inoculate 50 mL of Sabouraud dextrose broth for control and for various
concentrations of the molecules. The cultures were incubated for 16 hours and harvested by
centrifugation at 2700 rpm (856× g) for five min. The net weight of the cell pellet was determined.
Three mL of 25% alcoholic potassium hydroxide solution was added to each pellet and vortex mixed
for one min. Cell suspensions were transferred to sterile borosilicate glass screw-cap tubes and were
incubated in an 85 ◦C water bath for one hour. Following incubation, the tubes were allowed to cool.
Sterols were then extracted by addition of a mixture of 1 mL of sterile distilled water and 3 mL of
n-heptane followed by vigorous vortex mixing for 3 min. The heptane layer was transferred to a clean
borosilicate glass screw-cap tube and stored at −20 ◦C. Prior to analysis, 0.6 mL aliquot of sterol extract
was diluted five fold in 100% ethanol and scanned spectrophotometrically between 240 nm and 300 nm
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with a spectrophotometer (UV-Visible Spectrophotometer 2100, Thermo Fischer Scientific, Waltham,
MA, USA). The presence of ergosterol and the late sterol intermediate 24(28)-dehydroergosterol
(DHE) in the extracted sample results in a characteristic four-peaked curve. The absence of detectable
ergosterol in extracts was indicated by a flat line. A dose-dependent decrease in the height of the
absorbance peaks was evident and corresponded to decreased ergosterol concentration [26,50].
3.5. Molecular Docking
The 3D model structure of cytochrome P450 lanosterol 14-α demethylase of C. albicans was built
using homology modeling [37]. Molecular docking studies into a homology model of cytochrome P450
lanosterol 14 α-demethylase of C. albicans and into the E. coli DdlB enzyme (PDB entry: 1IOV [38]) were
performed using Glide v. 6.8 (Schrodinger, LLC, New York, NY, USA, 2015) to predict its antifungal
and antibacterial activity mode of action, respectively.
3.5.1. Homology Modeling Procedure for Cytochrome P450 Lanosterol 14α-Demethylase of C. albicans
The 3D model structure of cytochrome P450 lanosterol 14α-demethylase of C. albicans was built
using homology modeling. The amino acid sequence of the enzyme was obtained from the Universal
Protein Resource (http://www.uniprot.org/) (Accession Code: P10613), and sequence homologous
was obtained from Protein Data Bank (PDB) using Blast search. In literature, the structure of cytochrome
P450 lanosterol 14α-demethylase was developed homologically using crystal structure of lanosterol
14α-demethylase from C. albicans as template. Based on the result of blast search, we used the crystal
structure of human lanosterol 14-α DM (CYP51) with miconazole as a template for homology modeling
(PDB ID. 3I3K). A hidden Markov model (HMM) was generated from a sequence alignment for the
identification of sequence motifs and query family, which provides the information about which
residues are conserved in the consensus sequence. This information was used as constraints in the
generation of the protein sequence alignment. In addition, secondary structure prediction algorithms
SSpro [51] were used for alignment of C. albicans lanosterol 14α-demethylase to human lanosterol
14α-demethylase (DM) enzyme. The combination of sequence motifs and secondary structure provides
accurate picture of each helix. Alignment of C. albicans lanosterol 14α-demethylase with human
lanosterol 14α-demethylase enzyme was carried out using the automated alignment program in
PRIME v. 2.1 (Schrodinger LLC, New York, NY, USA). Following automated alignment, manual
inspection was made to ensure the conserved motifs, and loops were correctly aligned. The final model
of C. albicans lanosterol 14α-DM enzyme was developed using PRIME v2.1. The binding sites were
generated using SITEMAP v2.3 [52] (Schrodinger LLC, New York, NY, USA), and side chain and loops
around active binding site (site with highest sitemap score) were refined using Prime refinement tool.
The quality of generated C. albicans lanosterol 14 α-demethylase model was assessed by using the
well-validated programs PROCHECK [53] and WHATIF [37,54].
3.5.2. Molecular Docking Study into E. coli DdlB Enzyme
Molecular docking study was performed in Maestro 9.1 using Glide v. 6.8 (Schrodinger LLC).
All compounds were built using Maestro build panel and optimized to lower energy conformers using
Ligprep v3.5 (Schrodinger, Inc., New York, NY, USA). The coordinates for E. coli DdlB enzyme were
taken from RCSB Protein Data Bank and prepared for docking using ‘protein preparation wizard’ in
Maestro v10.3. The bond orders and formal charges were added for hetero-groups and hydrogen’s
were added to all atoms in the structure. Side chains that are not close to the binding cavity and do not
participate in salt bridges were neutralized and termini were capped by adding ACE and NMA residue.
After preparation, the structure was refined to optimize the hydrogen bond network using OPLS_2005
force field. The minimization was terminated when the energy converged or the RMSD reached a
maximum cutoff of 0.30 Å. The extra precision (XP) docking mode for all compounds was performed
on generated grid of protein structure [55]. The final evaluation of ligand-protein binding was done
with Glide score [17].
Molecules 2018, 23, 440 19 of 23
3.6. In Silico ADMET Prediction
A computational study of the synthesized compounds 4(a–f) and 6(a–f) was performed for
prediction of ADMET properties. The absorption, distribution, metabolism, elimination and toxicity
(ADMET) properties of all the synthesized compounds were predicted using Qikprop v. 3.5
(Schrodinger LLC). In the present study, we have calculated the molecular volume (M.V.), molecular
weight (M.W.), predicted octanol–water partition coefficient (log P o/w), number of hydrogen bond
acceptors (n-ON), number of hydrogen bonds donors (n-OHNH), percentage human oral absorption
(% ABS), Van der waals surface area of polar nitrogen and oxygen atoms (Polar Surface Area), Log S
(water solubility), BIPCaco-2 (apparent Caco-2 cell permeability), Log Khsa (binding to human serum
albumin) and Log HERG (toxicity study) [24].
3.7. In Vitro Cytotoxicity Studies
To explore the selective antifungal activity of the synthesized compounds in vitro cytotoxicity
study of the most active compounds 6c and 6f was performed against HeLa (human cervical cancer cell
line) and PC-3 (human prostate cancer cell line) using Sulforhodamine B (SRB) assay using Adriamycin
as positive control [45]. The images were captured using an Eclipse Ti-S Inverted Research Microscope
(Nikon, Tokyo, Japan). Image processing software used was NIS-Elements.
3.8. In Vivo Acute Oral Toxicity Study and Gross Behavioral Studies
Two of the newly synthesized compounds 6c and 6f, which are most potent among the synthesized
compounds, were further subjected to an in vivo acute oral toxicity study and gross behavioral study
as per the OECD guideline No. 425. Each group, consisting of six Swiss albino mice (18–22 gm weight,
overnight fasted), were kept in colony cage at 25 ± 2 ◦C with 55% relative humidity and 12 h of light
and dark cycle. A specified dose of 100, 250, 500, 750, 1000, 1500 and 2000 mg/kg body weight of
mice was administered orally as a single dose. The acute toxic symptoms and the behavioral changes
produced by the test compounds were observed continuously for 4 h periods at 8th, 12th and 24th h
on set of toxic symptoms and the gross behavioral changes were also recorded. These animals were
maintained for further 10 days with observation made daily. The in vivo acute oral toxicity study was
carried out at animal house at the Y.B. Chavan College of Pharmacy, Aurangabad IAEC approval
number CPCSEA/IAEC/P’col-52/2015-16/115 [26].
4. Conclusions
In this study, we have synthesized a suite of novel compounds 4(a–f) and 6(a–f) containing
chromone-pyrimidine coupled hybrid derivatives as antifungal and antibacterial agents using a
green synthetic protocol. The use of a green method, i.e., use of ionic liquid helped us in the
synthesis of the target derivatives in good yield. The eco-friendly reaction conditions, good to
excellent yields in a short reaction time and avoidance of cumbersome work-up procedures make
this process economically worthwhile for industrial application, with the additional advantage of
reusability of the catalyst. The in vitro antibacterial activity results suggest that compounds 4c, 6c and
6d possess potent in vitro antibacterial activity. The in vitro antifungal activity results suggest that
compounds 4e, 6e and 6f possess potent in vitro antifungal activity. A D-alanine-D-alanine ligase (DdlB)
enzyme assay study indicates that the synthesized derivatives have the ability to inhibit the DdlB
enzyme. The synthesized derivative 6f was found to be the most active antifungal agent; its mode
of action was studied using an ergosterol extraction and quantitation assay method. The results
of this test indicate that the synthesized compound 6f acts by inhibiting ergosterol biosynthesis by
inhibiting lanosterol 14α-demethylase enzyme. A molecular docking study was performed to predict
the mechanism of action of the synthesized derivatives. Further, analysis of the ADMET parameters
for the synthesized compounds performed using Qikprop v3.5 has revealed that these compounds
have good oral drug-like properties and which makes them suitable for development as future oral
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drug candidates. Moreover, the cytotoxicity study revealed that the compounds 6c and 6f did not show
any significant cytotoxicity against HeLa and PC-3 cell lines at the maximum evaluated concentration,
thus indicating the selectivity of their antimicrobial action. The newly synthesized compounds 6c
and 6f were also tested for their in vivo acute oral toxicity study and there was no mortality and no
significant behavioral changes observed in Swiss albino mice for the first 24 h. Thus, the synthesized
coupled compounds have shown excellent in vitro antimicrobial activity and compounds 4c, 4e, 6c and
6f could be in future further developed as lead antimicrobial molecules.
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